诺和诺德第三季度业绩超预期并上调全年展望，Wegovy 片剂销售表现亮眼
Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook
诺和诺德第三季度营收和调整后营业利润均高于预期，并上调全年业绩展望。第三季度营收为 792 亿丹麦克朗（119 亿美元），同比增长 4%；调整后营业利润为 317 亿丹麦克朗。公司目前预计，按固定汇率计算，全年调整后营收和营业利润增幅均在负 2% 至 2% 之间；此前预期为负 6% 至持平。Wegovy 片剂销售超过预期。
同一新闻，精选展示《诺和诺德因Wegovy口服药销售强劲上调全年业绩指引》
Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates.
The Danish weight-loss drug maker is looking to regain momentum following a tumultuous year in which it fell behind rival Eli Lilly.
The company updated its outlook to now see adjusted revenue and operating profit growth of between negative 2% and 2% at constant exchange rates. It previously saw full-year sales and operating profits, which it hiked in August, at negative 6% to flat for both metrics.
Sales in the third quarter came in at 79.2 billion Danish kroner ($11.9 billion), up 4% year-on-year and ahead of FactSet estimates of 73.6 billion kroner. Adjusted operating profit (EBIT) was 31.7 billion kroner, compared with the expected 28.6 billion kroner.
This is a breaking news story. Please refresh for updates.
来源：CNBC · cnbc.com